Blood-Based Exosomal A-Synuclein Aggregates as a Quantifiable Biomarker of Parkinson's Disease

Abstract

This study (W81XWH2010811/PD190043P1) aims to fulfill Objective 3 of the overall project titled as "Blood Based Exosomal alpha-Synuclein Aggregates as a Quantifiable Parkinson's Disease Biomarker". Aims of this study are to 1) cross-validate the misfolded alpha-Synuclein in red blood cell (RBC)-derived extracellular vesicles (EVs)as a biomarker of PD in a cohort US veterans, and 2) investigate the misfolded alphaSyn in RBC-derived EVs as a potential biomarker of prodromal PD in a cohort of US Vietnam veterans exposed to Agent Orange but who have not been diagnosed with PD. Studies to fulfill Objectives 1 and 2 (developing the blood test and testing in animal models and humans) are conducted by our collaborators at Iowa State University and University of Washington. The study has been launched at the Iowa City VA Medical Center and is behind recruitment target due to the COVID-19 pandemic, but we have expedited enrollment.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1220541

Entities

People

  • Ergun Y. Uc

Organizations

  • Veterans Administration Medical Center

Tags

Fields of Study

  • Biology

Readers

  • Clinical Trial Research.
  • Neurodegenerative Parkinson's Disease and Rickettsial Disease handbook, including the data level of dopamine, BC, neurons, and PD.
  • Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.